“We empower healthcare with AI-driven innovations”

DeepTek.ai plans to equip healthcare caregivers with the power of AI. It uses in-house innovative “assisted and augmented” (AaA) imaging-focused algorithmic tools designed by experts and covers a wide sphere of medical imaging like radiographs, CT scans, and MRI.

Amit Gandhi, Chief Business Officer, DeepTek.ai shares insights on his company’s focus on developing unique health technologies and products, and expansion plans.

Kindly share a few interesting facts about DeepTek.ai and the key milestones achieved so far?  

Founded in 2017, DeepTek.ai is amongst very few Radiology AI start-ups, which has successfully established commercial adoption of AI technology in clinical practice–creating clear and quantifiable value for patients, hospitals, and radiologists.

At the forefront of our achievements is Augmento, a US FDA cleared Radiology AI deployment platform. It represents a revolutionary convergence of smart reporting and cutting-edge AI technology, orchestrating a seamless optimization of radiology workflows.

Genki^TM, an AI-powered lung health screening solution by Deeptek.ai has ushered in a new era of precision diagnosis and care. In the ongoing TB Free initiative run by Greater Chennai Corporation (GCC) over 300,000 people have been screened since 2019 using the Genki^TM solution.

While AI can often appear as a ‘black box’, DeepTek.ai defies convention with its pioneering work in providing Responsible AI solutions. This integral feature suite within our solutions has garnered immense praise from medical professionals utilizing our services especially in Singapore.

DeepTek.ai’s journey is reinforced by esteemed equity partners such as TATA Capital Healthcare Fund II and NTT DATA, attesting to our vision and credibility. The company has established strategic collaborations with both Shimadzu Middle East & Africa and Shimadzu Asia Pacific. Through this partnership, DeepTek’s solutions are seamlessly integrated into Shimadzu devices, granting iti access to the robust market presence of Shimadzu, a recognized market leader in the field.

DeepTek.ai has successfully established commercial adoption of AI technology in clinical practice. Has this added value for patients, hospitals, and radiologists?

Through our AI-powered solutions, Deeptek.ai has successfully created substantial value for patients, hospitals, and radiologists in the field of medical imaging.

With Genki’s AI-powered lung health screening, patients benefit from faster and more accurate diagnoses of lung diseases such as tuberculosis, pneumonia, and lung cancer. Genki^TM analyzes Chest X Rays within a minute to automatically triage TB suspects. Only the suspects triaged positive on are sent for further confirmatory molecular tests. This reduces the need for conducting expensive molecular tests in a very large way – bringing down the overall costs. Instant results also ensure that suspected patients can be educated on-the-spot and cases are not lost for follow-up.

“Our roadmap includes regional expansion, particularly in APAC, the US, and Europe, guided by a steadfast commitment to R&D.”

DeepTek’s solutions have brought transformative changes to radiology workflows in hospitals. Augmento’s smart reporting and automation features have significantly reduced reporting turnaround times, enabling hospitals to handle higher volumes of cases efficiently. Genki^TM has helped increase the yield of finding TB patients several fold. In the context of our collaboration with the Greater Chennai Corporation, the yield has surged dramatically from 20 to 500 per 100,000 individuals screened.

Radiologists have benefited immensely from DeepTek’s AI technology. Augmento’s automation capabilities and smart reporting have alleviated radiologists’ workload, reducing the chances of errors and enhancing report accuracy.

Company aims to provide cutting-edge solutions powered by deep learning algorithms to bridge the wide gap in the imaging sector. Can you throw some more light on your plans?

Our mission revolves around empowering healthcare with AI-driven innovations. As we journey forward, our roadmap includes regional expansion, particularly in APAC, the US, and Europe, guided by a steadfast commitment to research and development. We envision to emerge as the foremost global hub for X-ray reporting outsourcing. Furthermore, we are committed to pioneering AI solutions in X-ray imaging, positioning ourselves as leaders in delivering exceptional AI deployment platforms to hospitals and imaging centers. Through these platforms, we aim to substantially enhance productivity, diagnostic capabilities, and more, ultimately reshaping the medical landscape in profound ways.

Can you tell us more about your breakthrough AI-powered Radiology Workflow Management Solution, Augmento? What are its unique features of the product?

DeepTek’s Augmento is India’s first US FDA Cleared Radiology AI deployment platform that seamlessly optimizes the radiology workflow.This innovative solution revolutionizes radiology workflows with a blend of smart reporting and cutting-edge AI technology, boosting both efficiency and accuracy.

Imagine a platform that seamlessly connects all players in the radiology ecosystem with a simple click. Augmento does just that, enhancing communication and slashing the time it takes to generate radiology reports. This means faster insights into patient conditions, leading to more precise diagnoses and improved care.

But Augmento doesn’t stop there. It’s an all-in-one tool that not only streamlines day-to-day operations but also simplifies image sharing through a user-friendly interface. Built-in communication and report distribution features make collaboration smoother than ever.

What’s even more impressive is that Augmento is vendor-neutral, capable of seamlessly integrating AI models developed by DeepTek.ai or other sources directly into existing workflows. This adaptability means healthcare providers can tailor their AI use to match their unique needs, without disrupting their established processes. Augmento has also been adopted by the esteemed Singapore Healthtech Agency, now known as Synapxe. Augmento is a crucial component of AIIM.SG, a groundbreaking platform aimed at accelerating the adoption of AI-powered medical imaging diagnostics.

“We envision to emerge as the foremost global hub for X-ray reporting outsourcing.”

Which clients and regions do you cater to in Asia and globally? Have your efforts to expand brand visibility and generate interest from key markets evoked any interest from investors so far?

Deeptek’s reach spans continents, serving as a pivotal player in the healthcare sectors across Asia-Pacific. Leading hospitals and imaging centers in Japan, Singapore, Thailand, the Philippines, Nigeria, and Kenya have all benefited from Deeptek’s solutions.

A strategic partnership with Synapxe, has propelled Augmento into the heart of Singapore’s health system. Having obtained US FDA clearance for Augmento, we now have our sights set on expansion across the US and Europe. We are set to introduce Augmento X Ray, an innovative Chest X-Ray Reporting Automation Tool tailored for these regions.

Investor interest has been a harmonious note in Deeptek’s journey. A USD 10 million injection from a Series A round led by Tata Capital Healthcare Fund, along with contributions from Pentathlon Ventures and GHV Accelerator, marked a significant milestone in 2022. Prior to this, NTT DATA’s seed funding had already set the tone for Deeptek’s trajectory.

Key partnerships with industry players like Shimadzu Asia Pacific, BJC Healthcare, and Shimadzu Middle East have further amplified our global footprint.

How has the company performed financially so far and your revenue outlook for next few years?

Presently, the majority of our revenue originates from markets beyond India, with approximately two-thirds stemming from the Asia Pacific region. Looking ahead to the next two to three years, our target is to achieve revenues surpassing US $15 million.

*This interview was first published in the October 2023 edition of BioVoice News eMagazine.